MedElevator
Войти в исследования Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026
Triglyceride-Glucose Index in Parotid Gland Tumours: A Novel Biomarker for Differentiating Warthin Tumour and Pleomorphic Adenoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dogan Remzi, Kucuk Ramazan Bahadır, Yenigun Alper, Dogan Elif Ece, Ozturan Orhan
Аннотация
INTRODUCTION: Pleomorphic adenoma and Warthin tumour are the two most common benign parotid gland tumours with distinct histological and clinical profiles. Recent studies suggest a potential link between metabolic disturbances-particularly insulin resistance-and the development of Warthin tumours. The triglyceride-glucose (TyG) index has emerged as a simple, cost-effective biomarker of insulin resistance. This study aimed to investigate the potential role of the TyG index in differentiating between pleomorphic adenoma and Warthin tumour.
METHODS: A retrospective cross-sectional study was conducted on patients histopathologically diagnosed with pleomorphic adenoma (n = 31) or Warthin tumour (n = 22), and compared with healthy controls (n = 58). Fasting glucose and triglyceride levels were used to calculate the TyG index. Statistical analyses included t-tests, ANOVA, and Bonferroni-corrected post hoc comparisons, with a significance threshold of p < 0.05.
RESULTS: No significant differences were observed in age, sex, BMI or TyG index between the tumour group and controls. However, the TyG index was significantly higher in the Warthin tumour group (4.91 ± 0.28) compared to the pleomorphic adenoma (4.68 ± 0.31, p = 0.006) and control groups (4.72 ± 0.23, p = 0.033). No difference was found between the pleomorphic adenoma and control groups.
CONCLUSION: The TyG index is significantly elevated in patients with Warthin tumours, supporting its potential role as a simple, non-invasive biomarker to aid in the differential diagnosis of benign parotid tumours.
METHODS: A retrospective cross-sectional study was conducted on patients histopathologically diagnosed with pleomorphic adenoma (n = 31) or Warthin tumour (n = 22), and compared with healthy controls (n = 58). Fasting glucose and triglyceride levels were used to calculate the TyG index. Statistical analyses included t-tests, ANOVA, and Bonferroni-corrected post hoc comparisons, with a significance threshold of p < 0.05.
RESULTS: No significant differences were observed in age, sex, BMI or TyG index between the tumour group and controls. However, the TyG index was significantly higher in the Warthin tumour group (4.91 ± 0.28) compared to the pleomorphic adenoma (4.68 ± 0.31, p = 0.006) and control groups (4.72 ± 0.23, p = 0.033). No difference was found between the pleomorphic adenoma and control groups.
CONCLUSION: The TyG index is significantly elevated in patients with Warthin tumours, supporting its potential role as a simple, non-invasive biomarker to aid in the differential diagnosis of benign parotid tumours.